PD-1 和 PD-L1 抑制剂市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按类型(PD-1 抑制剂和 PD-L1 抑制剂)、应用和地理划分。

市场快照

CAGR
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: >18.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

研究的 PD-1 和 PD-L1 抑制剂市场预计在预测期内的复合年增长率接近 18.5%。导致市场增长的主要因素是各种癌症的全球患病率急剧上升,以及各地区老年人口的增加,主要是在发达经济体和新兴经济体。例如,根据世界卫生组织的报告,癌症是全球主要死因,估计有 960 万人死亡,肺癌被确定为最常见的死因,2018 年有 176 万人死亡。因此,患者数量的增加导致市场需求增加,推动了预测期内全球市场的增长。

报告范围

程序性细胞死亡蛋白 1 (PD-1) 抑制剂和程序性细胞死亡配体 1 (PD-L1) 抑制剂是一组新型检查点抑制剂抗癌药物,可阻断存在于细胞表面的 PD-1 和 PDL1 免疫检查点蛋白的活性。细胞。这些免疫检查点抑制剂在组​​织同种异体移植后的妊娠中也很活跃,并成为几种癌症免疫治疗的一线治疗方法。特定染色解释的指示定义了肿瘤 PD-L1 状态。

Type of Inhibitors
PD-1 Inhibitors
PD-L1 Inhibitors
Application
Hodgkin Lymphoma
Kidney Cancer
Melanoma
Non-small Cell Lung Cancer
Other Applications
End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America
United states
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

PD-1 抑制剂细分市场预计将在 PD-1 和 PD-L1 抑制剂市场占有最大的市场份额

预计 PD-1 抑制剂部门将在预测期内占最大收入,该部门的主导地位可归因于研究活动量的增加、批准以及这些药物(如 nivolumab 和 pembrolizumab)的处方增加。此外,越来越多地采用派姆单抗 (KEYTRUDA),这是自 2014 年获得批准以来的第一个 PD-1 抑制剂,因为它已被证明可有效治疗多种 FDA 批准的适应症,如黑色素瘤、非小细胞肺癌 (NSCLC)、头颈部鳞状细胞癌细胞癌(HNSCC),以及其他在全球范围内高度流行的疾病,推动了细分市场的增长。另一方面,由于 durvalumab (IMFINZI) 的采用率急剧上升,预计 PD-L1 抑制剂细分市场在预测期内的复合年增长率最快,avelumab(BAVENCIO)和该领域的其他公司。主要参与者在这些产品开发方面的巨额投资进一步推动了该细分市场在预测期内推动全球市场收入。

cancer-image

PD-1 抑制剂细分市场预计将在 PD-1 和 PD-L1 抑制剂市场占有最大的市场份额

预计北美将在整个预测期内主导整个 PD-1 和 PD-L1 抑制剂市场。这种主导地位是由于各种慢性疾病的日益流行,如糖尿病、皮肤癌、尿路上皮癌、肺癌,以及在预测期内美国大量婴儿潮一代的存在需要有效的治疗。例如,根据美国癌症协会对 2020 年的估计,肺癌是第二常见的癌症,导致男性和女性死亡 135,720 人。统计数据还报告说,在美国,大约 13% 的肺癌是小细胞肺癌 (SCLC) 和 84% 的非小细胞肺癌 (NSCLC),预计未来还会继续,从而导致对这些肺癌的需求增加产品推动了该地区的市场。

PD-1 and PD-L1 Inhibitors Market

竞争格局

PD-1 和 PD-L1 抑制剂市场竞争适度,由几个主要参与者组成。一些公司正在通过采取收购和合并、研究合作等各种策略来扩大其市场地位,而另一些公司则正在投资临床试验,以扩大现有药物对其他适应症的治疗,以解决疾病负担驱动未解决的挑战市场份额。例如,2019 年 6 月,默克公司的 pembrolizumab (KEYTRUDA) 获得美国 FDA 的加速批准,用于治疗在铂类化疗和至少一种其他先前治疗方案中或之后出现疾病进展的转移性 SCLC 患者,即在预测期内可能会提高市场份额。目前在收入方面主导该行业的主要参与者很少是F. Hoffmann-La Roche AG、Merck & Co. Inc.、Regeneron Pharmaceuticals Inc.、AstraZeneca PLC 和 Bristol-MyersSquibbCompany。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Investments in R&D and Clinical Trials by Bio-pharmaceutical Industries

      2. 4.2.2 Increased Encouragement Initiatives by the Regulatory Authorities with Favorable Approvals and Special Designations

      3. 4.2.3 Growing Burden of Different Cancers

    3. 4.3 Market Restraints

      1. 4.3.1 Risk of Complications Associated with the Highly Expensive Oncology Treatment

      2. 4.3.2 Challenges in Development with Uncertainty in Regulatory Process and High Costs of Tedious Clinical Trials

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Type of Inhibitors

      1. 5.1.1 PD-1 Inhibitors

      2. 5.1.2 PD-L1 Inhibitors

    2. 5.2 Application

      1. 5.2.1 Hodgkin Lymphoma

      2. 5.2.2 Kidney Cancer

      3. 5.2.3 Melanoma

      4. 5.2.4 Non-small Cell Lung Cancer

      5. 5.2.5 Other Applications

    3. 5.3 End User

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Online Pharmacies

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United states

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bristol-Myers Squibb Company

      2. 6.1.2 Merck & Co.

      3. 6.1.3 F. Hoffmann-La Roche AG

      4. 6.1.4 Sanofi AG

      5. 6.1.5 Amgen Inc.

      6. 6.1.6 Gilead Sciences Inc.

      7. 6.1.7 AstraZeneca PLC

      8. 6.1.8 Novartis AG

      9. 6.1.9 Pfizer Inc.

      10. 6.1.10 Regeneron Pharmaceuticals Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The PD-1 and PD-L1 Inhibitors Market market is studied from 2018 - 2026.

The PD-1 and PD-L1 Inhibitors Market is growing at a CAGR of >18.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Bristol‑Myers Squibb Company, Regeneron Pharmaceuticals Inc, AstraZeneca plc, F. Hoffmann-La Roche AG, Merck & Co Inc are the major companies operating in PD-1 and PD-L1 Inhibitors Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!